Wellington Management Group LLP Purchases Shares of 59,584 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Wellington Management Group LLP acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 59,584 shares of the biopharmaceutical company's stock, valued at approximately $1,185,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 130,918.8% during the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company's stock valued at $45,968,000 after buying an additional 2,965,310 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company's stock valued at $33,702,000 after acquiring an additional 287,300 shares during the last quarter. Integral Health Asset Management LLC bought a new stake in Catalyst Pharmaceuticals in the second quarter worth approximately $4,260,000. Dimensional Fund Advisors LP increased its stake in shares of Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock worth $46,479,000 after purchasing an additional 263,099 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $4,936,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CPRX shares. Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, November 11th. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Finally, Stephens began coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $31.14.

Insider Buying and Selling

In other news, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Trading Down 0.9 %

CPRX traded down $0.19 during midday trading on Friday, reaching $21.27. The company's stock had a trading volume of 1,753,179 shares, compared to its average volume of 1,169,952. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.12 and a twelve month high of $24.27. The stock has a market cap of $2.54 billion, a P/E ratio of 18.03, a PEG ratio of 3.35 and a beta of 0.75. The company has a fifty day simple moving average of $21.75 and a 200 day simple moving average of $19.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.